The Implications of Dystrophin-Specific T cells for DMD gene Correction
The Implications of Dystrophin-Specific T cells for DMD gene Correction
批准号:
8377171
负责人:
Jerry Roy Mendell
金额:
$36.7万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressBloodBlood CirculationBlood VesselsCD8B1 geneCanis familiarisCellular ImmunityClinical ProtocolsClinical TrialsDiseaseDuchenne muscular dystrophyDystrophinEnrollmentEnsureEpitopesExhibitsFiberFollow-Up StudiesFrequenciesGene ExpressionGenesGentamicinsGlucocorticoidsGoalsImmuneImmune systemImmunityInduced MutationInflammatoryInstructionKnowledgeLearningLegLocationMacaca mulattaModelingMusMuscleMuscle FibersMuscular DystrophiesMutateMutationPathogenesisPatientsPhasePhenotypePredictive FactorPropertyProteinsResearchRoleStagingSystemT cell responseT-LymphocyteTestingTransgenesbaseclinical efficacyeffective therapyexperiencefollow-upgene correctiongene replacementgene replacement therapygene therapyinclusion criteriamicro-dystrophinminiaturizenovelpre-clinicalsuccesstransgene expressiontreatment programtreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (See instructions): The Implications of Dystrophin-Speclfic T cells for DMD Gene Correction Proof-of-principle studies in mouse and dog models of Ducheime muscular dystrophy (DMD) have established that gene replacement therapy is a promising treatment strategy. Attempts to apply the tenets learned from pre-clinical to clinical protocols did not predict dystrophin-specific T cells targeting novel epitopes on muscle fibers downstream of the mutation. In one case these were expressed on revertant fibers, a finding contrary to the axiom that forecasts a tolerizing role for these fibers. Another treatment paradigm, gentamicin-induced mutation suppression, proved equally confounding because dystrophin-specific T cells were isolated fi-om the blood and muscle following treatment. These observations require further study to achieve success in gene correction strategies for DMD. In Aim 1 we will characterize the properties of dystrophin-specific T cells in the blood and muscle of DMD patients with well characterized mutations to
determine how many patients exhibit cellular immunity to dystrophin and define the location of cognate selfepitopes within the mutated dystrophin protein. We will examine the effector fimctions of CD4+ and CD8+ T cells that are dystrophin specific. In Aim 2 we will look specifically at the role of glucocorticoids in modulating T cell response in a designated three-month treatment program of naive subjects. Here we anticipate a T cell phenotype change fi-om effector/inflammatory to a regulatory/suppressor role. In Aim 3 we will perform a vascular delivery clinical gene transfer study using AAVS.MCK.micro-dystrophin. We can achieve high levels of muscle fiber transduction through vascular delivery of transgene to specific leg muscles in the rhesus macaque. This sets the stage for clinical efficacy. The study inclusion criteria include currently identified immune barriers based on prior experience and will add findings that emerge from Projects 1 and 2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dual-vector mediated mini-dystrophin restoration of function in mdx model of DMD
-
批准号:8879230
-
项目类别:
-
资助金额:$18.31万
-
财政年份:2014
-
负责人:Jerry Roy Mendell
-
依托单位:
Dual-vector mediated mini-dystrophin restoration of function in mdx model of DMD
-
批准号:8770895
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2014
-
负责人:Jerry Roy Mendell
-
依托单位:
Vascular Delivery of alpha-Sarcoglycan for LGMD2D
-
批准号:8237961
-
项目类别:
-
资助金额:$104.13万
-
财政年份:2011
-
负责人:Jerry Roy Mendell
-
依托单位:
Vascular Delivery of alpha-Sarcoglycan for LGMD2D
-
批准号:8334425
-
项目类别:
-
资助金额:$52.24万
-
财政年份:2011
-
负责人:Jerry Roy Mendell
-
依托单位:
Vascular Delivery of alpha-Sarcoglycan for LGMD2D
-
批准号:8546147
-
项目类别:
-
资助金额:$49.63万
-
财政年份:2011
-
负责人:Jerry Roy Mendell
-
依托单位:
The Implications of Dystrophin-Specific T cells for DMD gene Correction
-
批准号:8032751
-
项目类别:
-
资助金额:$31.63万
-
财政年份:2010
-
负责人:Jerry Roy Mendell
-
依托单位:
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy
-
批准号:8294415
-
项目类别:
-
资助金额:$135.4万
-
财政年份:2010
-
负责人:Jerry Roy Mendell
-
依托单位:
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy
-
批准号:8473891
-
项目类别:
-
资助金额:$126.3万
-
财政年份:2010
-
负责人:Jerry Roy Mendell
-
依托单位:
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy
-
批准号:8685775
-
项目类别:
-
资助金额:$127.87万
-
财政年份:2010
-
负责人:Jerry Roy Mendell
-
依托单位:
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy
-
批准号:8133364
-
项目类别:
-
资助金额:$136.0万
-
财政年份:2010
-
负责人:Jerry Roy Mendell
-
依托单位:
Administrative Core
-
批准号:8032763
-
项目类别:
-
资助金额:$9.17万
-
财政年份:2010
-
负责人:Jerry Roy Mendell
-
依托单位:
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy
-
批准号:7989633
-
项目类别:
-
资助金额:$140.01万
-
财政年份:2010
-
负责人:Jerry Roy Mendell
-
依托单位:
Developing Clinical Outcomes for Gene Transfer
-
批准号:7663824
-
项目类别:
-
资助金额:$17.01万
-
财政年份:2008
-
负责人:Jerry Roy Mendell
-
依托单位:
CLINICAL TRIAL: SIX-MONTH (26 WEEKS) CLINICAL TRIAL OF GENTAMICIN IN DUCHENNE MD
-
批准号:7718632
-
项目类别:
-
资助金额:$0.17万
-
财政年份:2007
-
负责人:Jerry Roy Mendell
-
依托单位:
Developing Clinical Outcomes for Gene Transfer
-
批准号:7509209
-
项目类别:
-
资助金额:$28.1万
-
财政年份:2007
-
负责人:Jerry Roy Mendell
-
依托单位:
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery (U54)
-
批准号:7691714
-
项目类别:
-
资助金额:$211.27万
-
财政年份:2007
-
负责人:Jerry Roy Mendell
-
依托单位:
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery (U54)
-
批准号:7495589
-
项目类别:
-
资助金额:$205.16万
-
财政年份:2007
-
负责人:Jerry Roy Mendell
-
依托单位:
Dystrophin Restoration
-
批准号:7328072
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2007
-
负责人:Jerry Roy Mendell
-
依托单位:
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery (U54)
-
批准号:7907724
-
项目类别:
-
资助金额:$155.53万
-
财政年份:2007
-
负责人:Jerry Roy Mendell
-
依托单位:
Implementing Newborn Screening for Duchenne Muscular Dystrophy in the Community
-
批准号:7406885
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2007
-
负责人:Jerry Roy Mendell
-
依托单位:
海外基金